Caris Life Sciences had its Relative Strength (RS) Rating upgraded from 68 to 73 Tuesday — a welcome improvement, but still short of the 80 or higher score you prefer to see.
When To Sell Stocks To Lock In Profits And Minimize Losses
This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the trailing 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history shows that the best stocks typically have an RS Rating north of 80 in the early stages of their moves. See if Caris Life Sciences can continue to show renewed price strength and clear that threshold.
While Caris Life Sciences is not near a proper buy point right now, see if it manages to form and break out of a proper chart pattern.
Caris Life Sciences showed 0% earnings growth in the latest quarterly report. Revenue increased 50%. The next quarterly results are expected on or around Aug. 12.
The company earns the No. 9 rank among its peers in the Medical-Research Equipment/Services industry group. Medpace Holdings, IQVIA Holdings and Centessa Pharma ADR are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Improved Technical Action?
